Merck Sharp & Dohme LLC acquires Harpoon Therapeutics, Inc. (2024)

Deal facts

Buyer: Merck Sharp & Dohme LLC
Target: Harpoon Therapeutics, Inc.
Deal value: Not disclosed
Announced: 7 January 2024
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

11 Mar 2024CompletedClosed
Merck Sharp & Dohme LLC completes acquisition of Harpoon Therapeutics, Inc.
INTRODUCTORY NOTE On March 11, 2024 (the “Closing Date”), Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Merck”), completed the previously announced acquisition of Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 (the “Merger Agreement”), by and among Harpoon, Merck, and Hawaii Merger Sub, I
Source

OpinionExit Mode editorial

We see a clear signal in the Merck Sharp & Dohme LLC acquisition of Harpoon Therapeutics, Inc. This transaction, announced on 7 January 2024 and now completed, represents a definitive shift from public markets to private ownership. The deal structure is straightforward: a full cash consideration that removes the target from the stock exchange. For the SME founder watching from the UK or beyond, this illustrates how a major pharmaceutical house can secure a specific technology platform without the distraction of quarterly earnings calls or public shareholder pressure.

The going private nature of this deal carries specific commercial mechanics that you must understand. When a buyer offers all cash, they are effectively buying certainty and speed. There is no share swap, which means no dilution for existing shareholders and no need to manage a new equity relationship post-close. However, this also means the target company loses its public funding runway. The buyer assumes all future risk and reward. In the healthcare sector, this often triggers rigorous regulatory scrutiny. While this deal crossed the US Atlantic, the principle holds that large incumbents acquiring smaller innovators will face competition reviews, such as those by the CMA in the UK or the FTC in the US, to ensure market dominance is not threatened. The all-cash structure suggests the buyer was confident enough to absorb these potential delays without needing a contingent value right or an earn-out to bridge a valuation gap.

We think the lesson here is about timing and structure. A cash deal signals that the buyer values the asset enough to pay a premium for immediate control, but it also demands that the target is ready to hand over the keys completely. The absence of a disclosed value in the public record does not diminish the strategic intent. It simply means the terms were negotiated privately to avoid market speculation. This approach protects the target from volatility during the transition period. It is a clean break that allows the new owners to integrate the technology into their own pipeline without external interference.

Your action item this week is to review your current cap table and identify any shareholders who might prefer a clean cash exit over a complex share-swap structure. If your business relies on long-term R&D that conflicts with public market expectations, prepare a one-page memo outlining how a full cash acquisition could accelerate your product roadmap by removing quarterly reporting burdens.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More going private deals More from Merck Sharp & Dohme LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history